Rituximab(利妥昔單抗)市場:現狀分析與預測(2023-2030年)

Rituximab Market: Current Analysis and Forecast (2023-2030)

出版日期: 2023年06月30日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

由於非霍奇金淋巴瘤患病率不斷上升，預計利妥昔單抗市場在預測期內將以 16% 的複合年增長率增長。非霍奇金淋巴瘤 (NHL) 在美國是一種相對常見的癌症，約佔所有癌症患者的 4%。截至 2022 年 3 月，美國癌症協會估計大約有 80,470 人，包括成人和兒童，將被診斷患有非霍奇金淋巴瘤。據估計，男性終生罹患非霍奇金淋巴瘤的風險為 42 分之一，女性為 52 分之一，這可能是由於目標人群不斷增加。

為了更好地了解利妥昔單抗行業的市場採用情況，市場包括北美（美國、加拿大、北美其他地區）、歐洲（德國、英國、法國、西班牙、意大利、歐洲其他地區）、亞太地區（中國）、日本、印度）。、亞太地區其他地區）和世界其他地區是根據其在世界其他地區的存在情況進行分析的。北美佔據市場主導佔有率，預計在預測期內將繼續如此。北美的醫療保健設施具有最高標準，並且由於有利的政策而可供大量人口使用，這使得許多人能夠負擔得起（即使不是不存在）醫療保健。此外，北美地區幾個發達國家人口中非霍奇金淋巴瘤患病率的增加、人口老齡化、技術進步以及醫療保健支出的增加是推動市場增長的主要因素。

Rituximab is a type of antibody therapy that can be used in combination with chemotherapy or alone to target cancer cells by attaching to the CD20 protein found on the surface of blood cells with cancer and some healthy blood cells. It can be used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and other blood vessel diseases such as granulomatosis with polyangiitis and microscopic polyangiitis by slowing or stopping the growth of cancer cells and decreasing joint pain and swelling.

The Rituximab Market is expected to grow at a strong CAGR of 16% during the forecast period owing to the rising prevalence of non-hodgkin lymphoma. In the US, non-Hodgkin lymphoma (NHL) is a relatively common cancer that affects approximately 4% of all cancer cases. As of March 2022, the American Cancer Society estimates that approximately 80,470 people, including both adults and children, will be diagnosed with NHL. The lifetime risk of developing NHL is estimated to be 1 in 42 for men and 1 in 52 for women, indicating that the growth of the target population is likely to contribute to a growth.

Based on the route of administration, the market is segmented into subcutaneous, intravenous, and parenteral. The intravenous (IV) category held a significant share of the market in 2022 as IV rituximab is administered through a vein, making it a quick and efficient way to deliver the drug to the patient's body. Moreover, IV rituximab is absorbed into the bloodstream quickly, allowing it to begin working faster than other forms of rituximab. Thus, these factors are driving the growth of the segment in the forecast period.

By application, the market is categorized into non-hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and others. The non-hodgkin lymphoma is anticipated to grow with significant CAGR during the forecast period. According to the World Health Organization, an estimated 5,000,000 new cases of non-Hodgkin's lymphoma (NHL) were diagnosed in 2020. In the United States, NHL accounts for nearly 4% of all cancer cases. The rising incidence of NHL is expected to drive significant demand for rituximab biosimilars in the market over the forecast period.

Based on distribution channel, the market is segmented into hospital pharmacy, online pharmacy, and others. The hospital pharmacy held a dominant share of the market in 2022 owing to the increasing patient population, and growing focus on patient safety. Moreover, as the number of prescriptions filled by hospitals continues to rise, so too will the demand for hospital pharmacies to manage and dispense these medications, thus having a positive impact on the segmental growth.

For a better understanding of the market adoption of the rituximab industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America held the dominant share of the market and is expected to do so even in the forecast period. The healthcare facilities in North America are of the highest standards and are accessible to the large population because of favorable policies making healthcare affordable to many if not all. Moreover, the increasing incidence of non-hodgkin lymphoma cases among the population, the aging population, technological advancements, and increasing healthcare spending in several developed nations of North America region are the major factors driving the growth of the market.

Some of the major players operating in the market include: Pfizer Inc.; Amgen Inc.; Viatris Inc.; F. Hoffmann-La Roche ; Dr. Reddy's Laboratories Ltd.; Zydus Group; Novartis AG; Teva Pharmaceutical Industries Ltd.; Hetero; and BioXpress Therapeutics SA.

1 MARKET INTRODUCTION

1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1. Research Process of the Rituximab Market
2.2. Research Methodology of the Rituximab Market
2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL RITUXIMAB MARKET COVID-19 IMPACT

6 GLOBAL RITUXIMAB MARKET REVENUE, 2020-2030F

7 MARKET INSIGHTS BY ROUTE OF ADMINISTRATION

7.1. Subcutaneous
7.2. Intravenous
7.3. Parenteral

8 MARKET INSIGHTS BY APPLICATION

8.1. Non-Hodgkin Lymphoma
8.2. Chronic Lymphocytic Leukemia
8.3. Rheumatoid Arthritis
8.4. Others

9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

9.1. Hospitals Pharmacy
9.2. Online Pharmacy
9.3. Others

10 MARKET INSIGHTS BY REGION

10.1. North America
- 10.1.1. United States
- 10.1.2. Canada
- 10.1.3. Rest of North America
10.2. Europe
- 10.2.1. Germany
- 10.2.2. France
- 10.2.3. U.K.
- 10.2.4. Italy
- 10.2.5. Spain
- 10.2.6. Rest of Europe
10.3. Asia Pacific
- 10.3.1. China
- 10.3.2. Japan
- 10.3.3. India
- 10.3.4. Rest of Asia Pacific
10.4. Rest of World